Cancer Research Meeting Calendar Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tjin Tham Sjin, R. M.
Right arrow Articles by Javaherian, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tjin Tham Sjin, R. M.
Right arrow Articles by Javaherian, K.
[Cancer Research 65, 3656-3663, May 1, 2005]
© 2005 American Association for Cancer Research

Cell and Tumor Biology

A 27-Amino-Acid Synthetic Peptide Corresponding to the NH2-Terminal Zinc-Binding Domain of Endostatin Is Responsible for Its Antitumor Activity

Robert M. Tjin Tham Sjin1, Ronit Satchi-Fainaro1, Amy E. Birsner1, V.M. Sadagopa Ramanujam2, Judah Folkman1 and Kashi Javaherian1

1 Vascular Biology Program, Department of Surgery, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts and 2 Division of Human Nutrition, Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas

Requests for reprints: Kashi Javaherian, Vascular Biology Program, Department of Surgery, Children's Hospital Boston, Karp Family Research Laboratories, Room 11.213, One Blackfan Circle, Boston, MA 02115. Phone: 617-919-2392; Fax: 617-739-5891; E-mail: kashi.javaherian{at}childrens.harvard.edu.

The first recombinant endostatin that elicited strong antitumor activity was expressed in Escherichia coli and administered as a suspension. Under these conditions, the protein retained its full antiangiogenic activity. Lack of requirement for a folded structure prompted us to investigate antitumor properties of synthetic peptides corresponding to different regions of endostatin. Here, we show that the entire antitumor, antimigration, and antipermeability activities of endostatin are mimicked by a 27-amino-acid peptide corresponding to the NH2-terminal domain of endostatin. This peptide contains three histidines that are responsible for zinc binding. Mutations of the zinc-binding histidines abolished its antitumor and antimigration activities, but not antipermeability properties.




This article has been cited by other articles:


Home page
 IOVSHome page
H. Zhao, H. Jin, Q. Li, Q. Gu, Z. Zheng, H. Wu, S. Ye, X. Sun, X. Xu, and P. C. P. Ho
Inhibition of Pathologic Retinal Neovascularization by a Small Peptide Derived from Human Apolipoprotein(a)
Invest. Ophthalmol. Vis. Sci., November 1, 2009; 50(11): 5384 - 5395.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T.-Y. Lee, R. M. Tjin Tham Sjin, S. Movahedi, B. Ahmed, E. A. Pravda, K.-M. Lo, S. D. Gillies, J. Folkman, and K. Javaherian
Linking Antibody Fc Domain to Endostatin Significantly Improves Endostatin Half-life and Efficacy
Clin. Cancer Res., March 1, 2008; 14(5): 1487 - 1493.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Shi, Y. Huang, H. Zhou, X. Song, S. Yuan, Y. Fu, and Y. Luo
Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin
Blood, October 15, 2007; 110(8): 2899 - 2906.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
C.R. Dass, T.M.N. Tran, and P.F.M. Choong
Angiogenesis Inhibitors and the Need for Anti-angiogenic Therapeutics
Journal of Dental Research, October 1, 2007; 86(10): 927 - 936.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. M. Becker, R. D. Wright, R. Satchi-Fainaro, T. Funakoshi, J. Folkman, A. L. Kung, and R. J. D'Amato
A Novel Noninvasive Model of Endometriosis for Monitoring the Efficacy of Antiangiogenic Therapy
Am. J. Pathol., June 1, 2006; 168(6): 2074 - 2084.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Celik, O. Surucu, C. Dietz, J. V. Heymach, J. Force, I. Hoschele, C. M. Becker, J. Folkman, and O. Kisker
Therapeutic Efficacy of Endostatin Exhibits a Biphasic Dose-Response Curve
Cancer Res., December 1, 2005; 65(23): 11044 - 11050.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. Ichinose, Y. Maeshima, Y. Yamamoto, H. Kitayama, Y. Takazawa, K. Hirokoshi, H. Sugiyama, Y. Yamasaki, K. Eguchi, and H. Makino
Antiangiogenic Endostatin Peptide Ameliorates Renal Alterations in the Early Stage of a Type 1 Diabetic Nephropathy Model
Diabetes, October 1, 2005; 54(10): 2891 - 2903.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
X. Zeng, J. Chen, Y. I. Miller, K. Javaherian, and K. S. Moulton
Endostatin binds biglycan and LDL and interferes with LDL retention to the subendothelial matrix during atherosclerosis
J. Lipid Res., September 1, 2005; 46(9): 1849 - 1859.
[Abstract] [Full Text] [PDF]

Home page
 Cold Spring Harb Symp Quant BiolHome page
M.A. GRANT and R. KALLUR
Structural Basis for the Functions of Endogenous Angiogenesis Inhibitors
Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 399 - 417.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.